TECTONIC THERAPEUTIC, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
TECTONIC THERAPEUTIC, INC. (TECX) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $23.20 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-11-06
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $23.20M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $24.00M.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $26.10M.
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $13.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-09-30 | $23.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $24.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $26.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.30M 10-K · filed 2025-03-20 |
| 2024-09-30 | $13.40M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $13.80M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.91M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.22M 10-K · filed 2024-03-14 |
| 2023-09-30 | $6.28M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $11.49M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $16.21M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.72M 10-K · filed 2023-03-23 |
| 2022-09-30 | $21.34M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $27.46M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $34.36M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $43.33M 10-K · filed 2022-03-17 |
| 2021-09-30 | $52.33M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $62.17M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $56.95M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $36.05M 10-K · filed 2021-03-18 |
| 2020-09-30 | $41.14M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $45.53M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $46.31M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $22.88M 10-K · filed 2020-03-16 |
| 2019-09-30 | $22.07M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $21.33M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $22.08M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $12.10M 10-K · filed 2019-03-25 |
| 2018-09-30 | $8.24M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $6.78M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |